Viktig sikkerhets- og forskrivningsinformasjon
What is Opdualag
Opdualag is a fixed-dose combination of nivolumab, a programmed cell death-1 inhibitor (anti-PD-1), and relatlimab, a lymphocyte activation gene-3 inhibitor (anti-LAG-3)1
Binding of PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in certain tumors, and blocking this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors.
Nivolumab
Nivolumab (anti-PD-1) is a human IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking interaction with its ligands, PD-L1 and PD-L2, and reducing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Relatlimab
Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocking its interaction with ligands, including MHC II, and reducing LAG-3 pathway-mediated inhibition of the immune response. Blocking this pathway promotes T-cell proliferation and cytokine secretion.
Combination of Nivolumab (anti-PD-1) and Relatlimab (anti-LAG-3)
The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) leads to enhanced T-cell activation compared to the activity of the individual antibodies alone. In syngeneic mouse tumor models, LAG-3 blockade potentiated the anti-tumor activity of PD-1 blockade, inhibiting tumor growth and promoting tumor regression.
Reference:
1425-NO-2500004 February 2025
We refer to the SmPC for full information on Opdualag®